HONG KONG – The collaboration between Merck & Co. Inc. and South Korean company Genexine Inc. is just a few steps away from tackling human papillomavirus (HPV)-associated cancers, with Genexine receiving the go-ahead from the South Korean Ministry of Food and Drug Safety (MFDS) for a phase Ib/II trial testing a combination vaccine.